Exclusive Summary

• - Off-patent legacy molecule with broad generic entry, enabling fast registration and distribution in multiple markets.
• - Addresses high-burden emergencies (septic shock, adrenal crisis, severe asthma), and 50/100 mg SKUs align with guideline dosing.
• - Listed on the WHO Essential Medicines List and recommended by major guidelines (e.g., 200 mg/day in septic shock), ensuring hospital and EMS demand.
• - FDA GMP plus readiness for ICH Zone IV stability supports access to hot/humid markets (SEA, Africa, LATAM) and public tenders.
• - Recurrent global shortages of sterile injectables create room for compliant, reliable supply at 60–85% discount versus originator to win share.